Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 30.798
NA - Nord America 13.248
EU - Europa 9.187
SA - Sud America 4.953
Continente sconosciuto - Info sul continente non disponibili 1.698
AF - Africa 627
OC - Oceania 244
Totale 60.755
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 12.614
US - Stati Uniti d'America 11.718
SG - Singapore 6.105
CN - Cina 4.644
IT - Italia 3.951
BR - Brasile 3.465
HK - Hong Kong 1.857
BD - Bangladesh 1.397
RU - Federazione Russa 835
TR - Turchia 760
MX - Messico 743
FR - Francia 703
KR - Corea 687
DE - Germania 628
ES - Italia 628
IN - India 607
CA - Canada 506
AR - Argentina 493
GB - Regno Unito 425
ID - Indonesia 409
JP - Giappone 377
FI - Finlandia 325
CO - Colombia 299
AU - Australia 222
NL - Olanda 209
EC - Ecuador 190
IQ - Iraq 180
SA - Arabia Saudita 180
PK - Pakistan 179
AT - Austria 178
PL - Polonia 169
CL - Cile 166
ZA - Sudafrica 144
PH - Filippine 118
VE - Venezuela 117
EG - Egitto 110
GR - Grecia 110
CH - Svizzera 109
PT - Portogallo 106
SE - Svezia 105
UA - Ucraina 97
CZ - Repubblica Ceca 91
MA - Marocco 88
PE - Perù 85
PY - Paraguay 72
KZ - Kazakistan 69
UZ - Uzbekistan 69
TW - Taiwan 64
IL - Israele 62
DZ - Algeria 61
RO - Romania 61
TN - Tunisia 61
MY - Malesia 60
NO - Norvegia 60
CR - Costa Rica 59
HU - Ungheria 49
TH - Thailandia 48
BE - Belgio 46
JM - Giamaica 45
KE - Kenya 45
AE - Emirati Arabi Uniti 44
HR - Croazia 38
SK - Slovacchia (Repubblica Slovacca) 37
MD - Moldavia 36
GT - Guatemala 34
NP - Nepal 34
BO - Bolivia 33
JO - Giordania 33
HN - Honduras 30
UY - Uruguay 30
ET - Etiopia 29
IE - Irlanda 29
DO - Repubblica Dominicana 28
AZ - Azerbaigian 27
LT - Lituania 25
OM - Oman 24
SI - Slovenia 24
DK - Danimarca 23
NZ - Nuova Zelanda 21
LB - Libano 19
AL - Albania 18
RS - Serbia 17
SN - Senegal 17
PS - Palestinian Territory 15
TT - Trinidad e Tobago 15
GE - Georgia 14
NI - Nicaragua 14
EE - Estonia 13
SV - El Salvador 13
SY - Repubblica araba siriana 13
PR - Porto Rico 12
BY - Bielorussia 11
IR - Iran 11
NG - Nigeria 11
LV - Lettonia 10
PA - Panama 10
AM - Armenia 9
AO - Angola 9
KG - Kirghizistan 9
LK - Sri Lanka 9
Totale 58.908
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 4.028
Hanoi 3.224
Singapore 2.632
San Jose 2.119
Hong Kong 1.785
Hefei 1.647
Ashburn 1.304
Milan 1.098
Council Bluffs 683
Seoul 639
Chicago 561
Rome 518
Los Angeles 469
Lauterbourg 397
New York 377
Da Nang 351
Haiphong 343
São Paulo 335
Dallas 324
Buffalo 311
The Dalles 304
Ha Long 291
Quận Bình Thạnh 247
Biên Hòa 246
Helsinki 244
Istanbul 236
Beijing 213
Hải Dương 210
Ninh Bình 198
Santa Clara 195
Thái Nguyên 191
Vũng Tàu 177
Melbourne 174
Can Tho 173
Moscow 168
Rio de Janeiro 151
Ankara 148
Bắc Ninh 145
Madrid 145
Jakarta 124
Figino 122
Boardman 120
Bắc Giang 120
Frankfurt am Main 118
Naples 116
Quận Một 113
Tokyo 111
Mexico City 109
Phủ Lý 107
Shanghai 107
Montreal 106
Quận Phú Nhuận 106
Toronto 102
Bogotá 98
Guangzhou 94
Turin 91
Quận Sáu 88
Santiago 84
Brasília 82
Phoenix 82
Thái Bình 79
Barcelona 77
Vinh 77
Genoa 76
London 76
Vienna 76
Curitiba 75
Baghdad 74
Quito 74
Buenos Aires 73
Riyadh 73
Lấp Vò 72
Medellín 72
Atlanta 71
Bologna 71
Paris 71
Jeddah 69
Quận Tân Phú 69
Belo Horizonte 68
Lang Son 68
Uyen Hung 68
Guadalajara 66
Lima 65
Điện Bàn 65
Dhaka 63
Karachi 62
Palermo 62
Porto Alegre 62
Hangzhou 61
Philadelphia 60
Amsterdam 59
Boston 59
Nuremberg 59
Vĩnh Tường 59
Houston 58
Quận Năm 58
Tashkent 58
Brooklyn 57
Manchester 56
Quảng Ninh 55
Totale 31.874
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 4.334
Classification criteria for autoinflammatory recurrent fevers 2.632
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 1.445
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 1.148
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 690
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 555
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus 492
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 439
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 430
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 425
Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides 419
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 417
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 401
Macrophage Activation Syndrome in Juvenile Systemic Lupus Erythematosus A Multinational Multicenter Study of Thirty-Eight Patients 401
Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? 395
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 390
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 380
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 380
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 378
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation 371
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs 362
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 358
Criteria to define response to therapy in paediatric rheumatic diseases 350
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis 349
Localized scleroderma in childhood is not just a skin disease 338
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 283
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 276
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 275
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 273
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 268
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 267
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 264
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 261
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 244
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1) 241
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 236
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 236
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 235
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project 234
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 233
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 232
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? 229
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 228
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis 228
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis 221
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicenter PRINTO study 221
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 217
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 216
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 214
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 213
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis 212
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 210
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis 206
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial 205
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 201
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus 201
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 201
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 200
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis 195
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases 187
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 185
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 183
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 182
Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) 182
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 180
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 180
A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate 179
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 178
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 177
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 177
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials 175
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis 174
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 173
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 173
Adalimumab in Juvenile Rheumatoid Arthritis Reply 171
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis 170
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 169
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 169
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 167
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis 167
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 164
The Paediatric Rheumatology International Trials Organisation Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis 163
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 162
Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry 158
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study 156
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 155
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 155
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study 152
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 151
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 149
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 147
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 147
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 145
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 145
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 143
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey 142
JIA, Today and Tomorrow 141
Porpora di Schönlein-Henoch in paziente con pregressa glomerulonefrite di Berger (Schönlein-Henoch purpura in patients with previous Berger's glomerulonephritis) 138
Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry 137
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use 137
Totale 32.840
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.564
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202510.043 0 0 0 0 605 129 1.200 822 1.717 1.474 1.228 2.868
2025/202644.632 10.069 7.688 3.113 4.583 1.858 1.286 3.311 1.998 2.212 2.449 2.400 3.665
2026/20276.080 2.036 1.899 2.145 0 0 0 0 0 0 0 0 0
Totale 60.755